Dr. Heinz Lenz, MD | Los Angeles, CA ...

Dr. Warren A. Chow

Claim this profile

City of Hope Comprehensive Cancer Center

Studies Melanoma
Studies Cancer
13 reported clinical trials
31 drugs studied

Area of expertise

1Melanoma
Warren A. Chow has run 5 trials for Melanoma. Some of their research focus areas include:
Stage IV
Stage III
BRAF positive
2Cancer
Warren A. Chow has run 3 trials for Cancer. Some of their research focus areas include:
Stage IV
NY-ESO-1 positive
HLA-A positive

Affiliated Hospitals

Image of trial facility.
UC Irvine Health/Chao Family Comprehensive Cancer Center
Image of trial facility.
City Of Hope Comprehensive Cancer Center

Clinical Trials Warren A. Chow is currently running

Image of trial facility.

TAB004 + Toripalimab

for Solid Cancers

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Image of trial facility.

Nivolumab + Ipilimumab + Sargramostim

for Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria

More about Warren A. Chow

Clinical Trial Related5 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Warren A. Chow has experience with
  • Nivolumab
  • Ipilimumab
  • GSK Adoptive Cell Therapy
  • Fludarabine
  • Cyclophosphamide
  • Letetresgene Autoleucel (lete-cel, GSK3377794)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Warren A. Chow specialize in?
Is Warren A. Chow currently recruiting for clinical trials?
Are there any treatments that Warren A. Chow has studied deeply?
What is the best way to schedule an appointment with Warren A. Chow?
What is the office address of Warren A. Chow?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security